Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Central Nervous System Disease
Research on central nervous system disease reported by scientists at National Institutes of Health
August 13th, 2008
"Based on previous preclinical evaluation in mice and monkeys, the chimeric TBEV/DEN4 Delta 30 virus, carrying the prM and E protein genes from a highly virulent Far Eastern strain of tick-borne encephalitis virus (TBEV) on the backbone of a nonneuroinvasive dengue type 4 virus (DEN4), has been identified as a promising live attenuated virus vaccine candidate against disease caused by TBEV. However, prior to use of this vaccine candidate in humans, its neurovirulence in nonhuman primates needed to be evaluated," scientists writing in the Journal of Virology report. "In the present study, we compared the neuropathogeneses of the chimeric TBEV/DEN4 Delta 30 virus;...
Source: Vaccine Weekly (2008-08-13)
|
